2[7]Arikian SR, Casciano J, Doyle JJ, et al. A pharmacoeconomic evaluation of two new products for the treatment ofoveractive bladder[J]. Monag Care Inte rface ,2000,13(2) :88.
3[8]Hill RP, Lubarsky DA, Phillips BB, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo [J]. Anesthesiology,2000,92(4) :958.
4[10]McCoy S, Blayney-Chandramouli J, Mutnick A. Using multiple pharmacoeconomic methods to condut a cost-effectiveness analysis of histamine H2-receptor antagonists[J]. Am J Health Syst Pharm, 1998, 55(Suppl 4):s8.
5[16]Schumacher GE. Multiattribute evaluation in formulary decision making as applied to calcium-channel blockers[J] .Am J Hosp Pharm,1991,48(2):301.
6TAKAHASHI H, HAYAKAWA I, AKIMOTO T. The history of the development and changes of quinolone antibacterial agents [J].Yakushigaku Zasshi, 2003,38 (2): 161-179.
7MINAMI S, HATTORI R, MATSUDA A. Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate [J]. Nippon Yakurigaku Zasshi, 2003,122(2) :161-178.
8NOMURA N, MITSUYAMA J, FURUTA Y, et al. In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone [J]. Jpn J Antibiot ,2002,55 (4) :412-439.
9NAGASAWA M, NAKAMURA S, MIYAZAKI M, et al. Phototoxicity studies of pazufloxacin mesilate, a novel parenteral quinolone antimicrobial agent-in vitro and in vivo studies[J]. Jpn J Antibiot,2002, 55 (3) :259-269.
10RUBINSTEIN E. History of quinolones and their side effects [J].Chemotherapy,2001,47 Suppl 3:3-8.
5Kaufman SE, Donnell RW, Hickey WS. Rationale and evidence for extended infusion of piperacillin-tazobactam[J]. Am J Health Syst Pharm,2011,68(16):1521.
6Yusuf E,Spapen H, Pierard D. Prolonged vs intermittent infusion of piperacillin/tazobactam in crtically ill patients:A narrative and systematic review[J]. J Crrit Care,2014,29(6):1089-1095.
7Falagas ME, Tansarli GS, Ikawa K, et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis[J]. Clin Infect Dis,2013,56(2):272-282.
8Eiki K, Junko K, Yasuyuki N, et al. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions[J]. Antimicrob Agents Chemother,2009,53(7): 2799-2803.
9Suyamah H, Ikawa K, Morikawa N, et al. Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration[J]. Jpn J Antibiot,2008,61(5): 303-313.
10De Waele J, Carlier M, Hoste E, et al. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis[J].Minerva Anestesiol,2014,21(6):389-395.
